Ages2Come
Menu
View all results →
Categories
⚡ Breaking
Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says Tim Cook to be paid $47mn as Apple’s executive chair Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says Tim Cook to be paid $47mn as Apple’s executive chair
Business / General

How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle

Source: bloombergMarkets June 23, 2026 · 10:00
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company’s hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, fo…
Read original article ← Back to General

The original article opens on the publisher's website.

More from General

View topic →